PPIs and Clopidogrel: Do We Have to Worry?

Kuritzky, Louis
December 2009
OB/GYN Clinical Alert;Dec2009, Vol. 26 Issue 8, p23
The article reports on the pharmacological relation between proton pump inhibitor (PPI) and clopidogrel in the U.S. It mentions that the antiplatelet effect of clopidogrel depends on its conversion and activation through the 2C19 pathway of the P450 system where the blockade of this pathway happens when a person do not have sufficient active 2C19. In relation, it suggests that PPI need not be avoided when treating acute coronary syndromes with clopidogrel or prasugrel.


Related Articles

  • Potential Interaction between Clopidogrel and Proton Pump Inhibitors. Howard, Patricia A.; Vacek, James L. // American Journal of Cardiovascular Drugs;2009, Vol. 9 Issue 6, p353 

    Clopidogrel is widely used in patients with acute coronary syndromes and following percutaneous coronary intervention with stent implantation. The antiplatelet action of clopidogrel is felt to be of critical importance for the reduction of abrupt thrombotic occlusion of stents, particularly with...

  • Clopidogrel and interaction with proton pump inhibitors: comparison between cohort and within person study designs. Douglas, Ian J.; Evans, Stephen J. W.; Hingorani, Aroon D.; Grosso, Anthony M.; Timmis, Adam; Hemingway, Harry; Smeeth, Liam // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;8/11/2012, Vol. 345 Issue 7869, p15 

    The article reports on research which was conducted to determine whether pharmacokinetic interaction between proton pump inhibitors and clopidogrel lead to harmful vascular events. A comparison between cohort and within person study designs was carried out as part of the research. The results...

  • Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis. Hutchinson, Carol; Geissler, Catherine A.; Powell, Jonathan J.; Bomford, Adrian // Gut;Sep2007, Vol. 56 Issue 9, p1291 

    Background and Aims: During the long-term treatment of patients with hereditary haemochromatosis (HH) the authors observed that proton pump inhibitors (PPI) reduced the requirement for maintenance phlebotomy. Gastric acid plays a crucial role in non-haem iron absorption and the authors performed...

  • PPIs, H. pylori, and Atrophic Gastritis: Putting the Issue to Rest? DiBaise, John K.; Thompson, Jon S. // American Journal of Gastroenterology;Dec1999, Vol. 94 Issue 12, p3403 

    Discusses research being done on the effect of acid suppression therapy on the development of atrophic gastritis in individuals infected with Helicobacter pylori. Reference to a study by L. Lundell, P. Miettinen, H. E. Myrvold et al., published in the 1999 issue of the "American Journal of...

  • Gastro-oesophageal reflux disease.  // BMJ: British Medical Journal (International Edition);1/14/2006, Vol. 332 Issue 7533, p88 

    The article discusses the causes, diagnosis and treatment of gastro-oesophageal reflux disease (GORD). The author reviews how GORD is present when the passage of gastric contents into the oesophagus causes symptoms or damages the mucosa. According to the author, genetic influences and lifestyle...

  • PPI treatment beneficial to patients with ulcer bleeding, according to meta-analysis.  // Formulary;Jun2007, Vol. 42 Issue 6, p391 

    The article focuses on the study that examines the benefits of proton-pump inhibitors (PPIs) for patients with ulcer bleeding. According to the study, the use of PPIs for ulcer bleeding effectively reduces the risk of bleeding and the need for surgical intervention and repeated endoscopic...

  • Impact of Long-Term Proton Pump Inhibitor Therapy on Gut Microbiota in F344 Rats: Pilot Study. Cheol Min Shin; Nayoung Kim; Yong Sung Kim; Ryoung Hee Nam; Ji Hyun Park; Dong Ho Lee; Yeong-Jae Seok; Yeon-Ran Kim; Joo-Hyon Kim; Jung Min Kim; Joo Sung Kim; Hyun Chae Jung // Gut & Liver;Nov2016, Vol. 10 Issue 6, p896 

    Background/Aims: To evaluate changes in gut microbiota composition following long-term proton pump inhibitor (PPI) treatment. Methods: Twenty-four-week-old F344 rats were fed diets with (n=6) or without (n=5) lansoprazole for 50 weeks. Profiles of luminal microbiota in the terminal ileum were...

  • Effect of Increasing Esomeprazole and Pantoprazole Doses on Acid Control in Patients with Symptoms of Gastro-Oesophageal Reflux Disease: A Randomized, Dose-Response Study. Wilder-Smith, Clive; Backlund, Anna; Eckerwall, Göran; Lind, Tore; Fjellman, Mia; Röhss, Kerstin // Clinical Drug Investigation;2008, Vol. 28 Issue 6, p333 

    Background and objective: In patients with gastro-oesophageal reflux disease (GORD), dose escalation or drug switching may be considered in those with symptoms that persist despite standard-dose proton pump inhibitor (PPI) therapy. This study set out to assess whether increasing the dosage of...

  • Finding ACCORD in the Management of Type 2 Diabetes? Elliott, William T. // Clinical Oncology Alert;May2010 Supplement, p1 

    The article examines the Action to Control Cardiovascular Risk in Diabetics (ACCORD) trial conducted to assess the efficacy of clopidogrel, dexlansoprazole and tamsulosin in treating type 2 diabetes. The trial, published in the March issue of "New England Journal of Medicine," tested the effects...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics